OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.
March 22, 2023
The systematic review summarized the impact of biologics targeting the IL-23/Th17 axis.
March 16, 2023
The phase 3 DISCOVER-1 and DISCOVER-2 studies were used to evaluate dactylitis resolution in guselkumab-treated patients with psoriatic arthritis through 1 year.
Polypharmacy, defined as ≥5 concomitant drugs, was significantly higher in patients with psoriatic arthritis when compared with controls (49% vs 17%, respectively).
March 13, 2023
Results demonstrate that guselkumab was well-tolerated in studies continuing for 1 to 2 years among patients with active psoriatic arthritis regardless of TNFi experience.
Higher baseline Disease Activity Index for Psoriatic Arthritis (DAPSA) was associated with reduced probability of achieving low disease activity or remission.
March 10, 2023
New pooled data from DISCOVER-1 and DISCOVER-2 show the injection biologic provided full resolution of dactylitis in three-fourths of patients by week 52.
March 09, 2023
A cohort analysis from Norway suggests women with active psoriatic arthritis or axial spondylitis are at greater risk of either elective or emergency delivery procedures.
March 03, 2023
Radiographic non-progressors treated with guselkumab achieved patient-reported minimal disease activity criteria of minimal pain and normalized physical function more often than radiographic non-responders.
February 23, 2023
Study results are the first to demonstrate that tofacitinib may be an effective treatment option for Chinese patients with active psoriatic arthritis.
February 20, 2023
Roy Fleischmann, MD, examined the necessity of performing repeated x-rays in patients with rheumatic disease as a part of disease management.